Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial

BACKGROUND: Toripalimab is a humanized immunoglobulin G(4) monoclonal antibody against programmed death 1. We aimed to investigate the efficacy and safety of toripalimab in combination with intensity-modulated radiotherapy (IMRT) for recurrent nasopharyngeal carcinoma (rNPC). METHODS: We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Yijun, You, Rui, Wang, Zhiqiang, Huang, Peiyu, Lin, Mei, Ouyang, Yanfeng, Xie, Yulong, Zou, Xiong, Liu, Youping, Duan, Chongyang, Liu, Yonglong, Gu, Chenmei, Liu, Rongzeng, Yang, Qi, Jiang, Rou, Zhang, Mengxia, Ding, Xi, Chen, Siyuan, Lin, Chao, Sun, Rui, Chen, Mingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593727/
https://www.ncbi.nlm.nih.gov/pubmed/34782428
http://dx.doi.org/10.1136/jitc-2021-003290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593727/
https://www.ncbi.nlm.nih.gov/pubmed/34782428
http://dx.doi.org/10.1136/jitc-2021-003290

Ejemplares similares